Revenues from drugs subject to price reduction under Inflation Reduction Act not essential for R&D

New research from the Center for Integration of Science and Industry at Bentley University shows that public companies with products subject to price negotiations in the first two years of the Inflation Reduction Act (IRA) were more profitable…

Continue Reading

News Source: medicalxpress.com